← FDA DRUG APPROVALS

FDA ANDA · ANDA212280

PREGABALIN CAPSULES, CV

Sponsor: CIPLA

APPLICATION
ANDA212280
TYPE
ANDA
ORIGINAL APPROVAL
2020-01-10
LATEST ACTION
2025-07-01
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

PREGABALINDiscontinued
PREGABALIN 225MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 150MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 75MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 25MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 300MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 200MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 100MG · CAPSULE · ORAL
PREGABALINDiscontinued
PREGABALIN 50MG · CAPSULE · ORAL

Approval history

2025-07-01Labeling · Supplement 10 · standardAP
2024-07-31Labeling · Supplement 8 · standardAP
2023-06-09Labeling · Supplement 6 · standardAP
2023-06-09Labeling · Supplement 2 · standardAP
2020-01-10UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →